BE522346A - - Google Patents
Info
- Publication number
- BE522346A BE522346A BE522346DA BE522346A BE 522346 A BE522346 A BE 522346A BE 522346D A BE522346D A BE 522346DA BE 522346 A BE522346 A BE 522346A
- Authority
- BE
- Belgium
- Prior art keywords
- sep
- inh
- tuberculosis
- treatment
- parts
- Prior art date
Links
- QRXWMOHMRWLFEY-UHFFFAOYSA-N Isoniazid Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 48
- 201000008827 tuberculosis Diseases 0.000 claims description 27
- 230000001225 therapeutic Effects 0.000 claims description 10
- 208000008128 Pulmonary Tuberculosis Diseases 0.000 claims description 8
- SRVJKTDHMYAMHA-WUXMJOGZSA-N Thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 150000001299 aldehydes Chemical class 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 claims description 5
- 230000002195 synergetic Effects 0.000 claims description 3
- TWBYWOBDOCUKOW-UHFFFAOYSA-N Isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 claims 1
- HLFCZZKCHVSOAP-DAMYXMBDSA-M sodium;(5Z)-5-(carbamoylhydrazinylidene)-1-methyl-6-oxo-2,3-dihydroindole-2-sulfonate Chemical compound [Na+].NC(=O)N/N=C/1C(=O)C=C2N(C)C(S([O-])(=O)=O)CC2=C\1 HLFCZZKCHVSOAP-DAMYXMBDSA-M 0.000 claims 1
- 229920001098 polystyrene-block-poly(ethylene/propylene) Polymers 0.000 description 401
- 239000000203 mixture Substances 0.000 description 24
- 230000000694 effects Effects 0.000 description 12
- 244000052616 bacterial pathogens Species 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 206010036790 Productive cough Diseases 0.000 description 7
- 210000003802 Sputum Anatomy 0.000 description 7
- 201000009910 diseases by infectious agent Diseases 0.000 description 7
- 229960005322 Streptomycin Drugs 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 229940042795 Hydrazides for tuberculosis treatment Drugs 0.000 description 3
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000001926 lymphatic Effects 0.000 description 3
- 230000002685 pulmonary Effects 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-Aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- RKPHTRVPGYGVQD-UHFFFAOYSA-N 4-amino-2-hydroxybenzoic acid;pyridine-4-carbohydrazide Chemical compound NNC(=O)C1=CC=NC=C1.NC1=CC=C(C(O)=O)C(O)=C1 RKPHTRVPGYGVQD-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 229940010383 Mycobacterium tuberculosis Drugs 0.000 description 1
- SKLUWKYNZNXSLX-UHFFFAOYSA-N N-(4-formylphenyl)acetamide Chemical compound CC(=O)NC1=CC=C(C=O)C=C1 SKLUWKYNZNXSLX-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 230000004523 agglutinating Effects 0.000 description 1
- MQIZXGIITBMAPU-UHFFFAOYSA-N aminooxymethanethioic S-acid Chemical compound NOC(S)=O MQIZXGIITBMAPU-UHFFFAOYSA-N 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 150000001717 carbocyclic compounds Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 229940042396 direct acting antivirals Thiosemicarbazones Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- -1 p-acetylamino-benzal- Chemical class 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 150000003584 thiosemicarbazones Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE522346A true BE522346A (ja) |
Family
ID=157649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE522346D BE522346A (ja) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE522346A (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2971887A (en) * | 1956-05-30 | 1961-02-14 | Horner Frank W Ltd | Inhibition of isoniazid acetylation |
-
0
- BE BE522346D patent/BE522346A/fr unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2971887A (en) * | 1956-05-30 | 1961-02-14 | Horner Frank W Ltd | Inhibition of isoniazid acetylation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2736103B2 (ja) | パーキンソン症候群の治療用医薬、およびその製造方法 | |
| EP0316993B1 (fr) | Compositions pharmaceutiques contenant un dérivé de l'acide 3-hydroxybutanoique choisi parmi les oligomères de cet acide et les esters de cet acide ou de ces oligomères avec du 1,3-butanediol | |
| Marsden et al. | Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase | |
| EP1283708B1 (fr) | Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant | |
| JP2020535190A (ja) | カンナビジオールによる脆弱ｘ症候群の処置 | |
| FR2530468A1 (fr) | Composition analgesique et anti-inflammatoire contenant de l'ibuprofen | |
| KR20210139293A (ko) | 폐동맥 고혈압 및 연관 폐동맥 고혈압 치료방법 및 매일 투여 | |
| EP0181142A2 (en) | A method of treating ulcerative colitis and colon cancer | |
| JP4306825B2 (ja) | インスリン抵抗性が関与する血管機能異常を伴う疾患の予防または治療剤 | |
| JPWO2007007757A1 (ja) | ＰＰＡＲγアゴニストを含有する医薬組成物 | |
| EP3429611B1 (fr) | Polycomplexes de composes poly-lysine pour la prevention et/ou la lutte contre la sclerose laterale amyotrophique | |
| ROBITZEK et al. | Isoniazid and its isopropyl derivative in the therapy of tuberculosis in humans: comparative therapeutic and toxicologic properties | |
| BE522346A (ja) | ||
| KR101072175B1 (ko) | 데커신 및/또는 데커시놀 안젤레이트, 또는 데커신및/또는 데커시놀 안젤레이트를 유효성분으로 하는당귀추출물을 포함하는 배뇨장애 치료제 및 부종 치료제조성물 | |
| EP0739629B1 (fr) | Nouvelles associations comprenant du (-)hydroxycitrate et présentant notamment de nouvelles activités thérapeutiques | |
| EP1815858A2 (fr) | Association entre un ligand des récepteurs actives par les proliférateurs de péroxisomes et un agent antioxydant et les compositions pharmaceutiques qui les contiennent | |
| JP2021147394A (ja) | 牛樟芝の酒酔い解消及び／又はアルコール代謝増加に用いる用途 | |
| JPH01186883A (ja) | 抗アテローム性動脈硬化症剤としてのｄｌ‐５‐〔（２ベンジル‐３，４‐ジヒドロ‐２Ｈ‐ベンゾピラン‐６‐イル）メチル〕チアゾリジン‐２，４‐ジオン | |
| WO2019232740A1 (zh) | 一种用于防治糖尿病的药物组合物及其用途 | |
| US3737552A (en) | Method of treating gonorrhea | |
| FR2520230A1 (fr) | Preparations medicamenteuses contenant un derive d'acide tetraiodothyro-carboxylique notamment pour le traitement de l'hypercholesterolemie | |
| CN114557992B (zh) | 一种复方药物组合物在制备治疗间质性肺炎药物中的应用 | |
| KR20060066177A (ko) | 데커신 및/또는 데커시놀 안젤레이트, 또는 데커신및/또는 데커시놀 안젤레이트를 유효성분으로 하는당귀추출물을 포함하는 간기능 치료제 조성물 | |
| JPH02215725A (ja) | 抗高脂血症剤 | |
| Stone | Candida endocarditis treated with a combination of antifungal chemotherapy and aortic valve replacement. |